Studies from University of Nebraska Medical Center Update Current Data on Factor Xa Inhibitors (Lower Mortality With Andexanet Alfa Vs 4-factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-related Major Bleeding In a Us...).

MLA

“Studies from University of Nebraska Medical Center Update Current Data on Factor Xa Inhibitors (Lower Mortality With Andexanet Alfa Vs 4-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Major Bleeding In a Us...).” Hematology Week, Nov. 2023, p. 487. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=173666905&authtype=sso&custid=ns315887.

APA

Studies from University of Nebraska Medical Center Update Current Data on Factor Xa Inhibitors (Lower Mortality With Andexanet Alfa Vs 4-factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-related Major Bleeding In a Us...). (2023). Hematology Week, 487.

Chicago

“Studies from University of Nebraska Medical Center Update Current Data on Factor Xa Inhibitors (Lower Mortality With Andexanet Alfa Vs 4-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Major Bleeding In a Us...).” 2023. Hematology Week, November, 487. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=173666905&authtype=sso&custid=ns315887.